EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Outcomes after transcatheter mitral valve implantation in valve‐in‐valve, valve‐in‐ring, and valve‐in‐mitral annular calcification

Hector A Alvarez-Covarrubias iD, Michael Joner, Marius Lutz, Erion Xhepa iD, N Patrick Mayr iD, Mark Lachmann, Salvatore Cassese iD, Tobias Rheude, Costanza Pellegrini, Sebastian Kufner, Heribert Schunkert, Adnan Kastrati iD und 3 weitere

Catheterization and Cardiovascular Interventions · 2024

DOI: 10.1002/ccd.31166 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Catheterization and Cardiovascular Interventions, 2024. Verfasst von Hector A Alvarez-Covarrubias und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiology, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany. Hauptthemen laut MEDLINE: Heart Valve Prosthesis, Mitral Valve, Heart Valve Prosthesis Implantation, Calcinosis. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

We aimed to evaluate transcatheter mitral valve implantation (TMVI) using predominantly balloon‐expandable transcatheter heart valves (THV) in patients with a landing zone for a percutaneously delivered prosthesis.

Background

Patients with a degenerated mitral valve bioprosthesis, annuloplasty ring, and mitral annulus calcification (MAC) considered at high surgical risk currently represent a treatment challenge. TMVI is an alternative treatment option.

Methods

Retrospective analysis of patients with symptomatic degenerated mitral valve bioprosthesis, or annuloplasty ring, and MAC treated with TMVI between November 2011 and April 2021. Endpoints were defined according to Mitral Valve Academic Research Consortium (MVARC) criteria and included device and procedure success at 30 days as well as mortality at 30 days and 1 year after the procedure.

Results

A total of 77 patients underwent TMVI (valve in valve [ViV = 56], valve in ring [ViR = 11], and valve in MAC [ViMAC = 10]). There was a trend toward higher technical success (all = 93.5%, ViV = 96.4%, ViR = 90.9%, ViMAC = 80%, p = 0.06) and lower 30‐day (all = 11.7%, ViV = 10.7%, ViR = 9.1%, ViMAC = 20%, p = 0.49) and 1‐year mortality (all = 26%, ViV = 23.2%, ViR = 27.3%, ViMAC= 40%, p = 0.36) after ViV and ViR compared to ViMAC.

Conclusion

TMVI represents a reasonable treatment option in selected patients with MAC or who are poor candidates for redo mitral valve surgery. Technical success and survival up to 1 year were not significantly dependent on the subgroup in which TMVI was performed.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Heart Valve ProsthesisMitral ValveHeart Valve Prosthesis ImplantationCalcinosisProsthesis DesignCardiac CatheterizationBioprosthesisMitral Valve AnnuloplastyHumansMaleRetrospective StudiesFemaleAgedTreatment OutcomeTime FactorsRisk FactorsAged, 80 and overRecovery of FunctionProsthesis FailureMiddle AgedHeart Valve DiseasesRisk Assessment

Stichwörter der Autor:innen

transcatheter mitral valve implantationvalve‐in‐mitral annulus calcificationvalve‐in‐ringvalve‐in‐valve

Autor:innen und Institutionen

  • Department of Cardiology, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.
  • Departamento de Cardiología, Hospital de Cardiología, Centro Médico Nacional Siglo XXI, IMSS, Mexico City, Mexico.
  • DZHK (German Center for Cardiovascular Research), Partner Site Munich Heart Alliance, Munich, Germany.
  • Department of Cardiac Surgery, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.
  • Institut für Anästhesiologie, Deutsches Herzzentrum München, Technische Universität München, Munich, Germany.
  • First Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany.

ORCID-Profile: Hector A Alvarez-Covarrubias, Erion Xhepa, N Patrick Mayr, Salvatore Cassese, Adnan Kastrati, Magdalena Erlebach

Zitieren

APA

Alvarez-Covarrubias, H. A., Joner, M., Lutz, M., Xhepa, E., Mayr, N. P., Lachmann, M., Cassese, S., Rheude, T., Pellegrini, C., Kufner, S., Schunkert, H., Kastrati, A., Erlebach, M., Lange, R., & Ruge, H. (2024). Outcomes after transcatheter mitral valve implantation in valve‐in‐valve, valve‐in‐ring, and valve‐in‐mitral annular calcification. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31166

Vancouver

Alvarez-Covarrubias HA, Joner M, Lutz M, Xhepa E, Mayr NP, Lachmann M, et al. Outcomes after transcatheter mitral valve implantation in valve‐in‐valve, valve‐in‐ring, and valve‐in‐mitral annular calcification. Catheterization and Cardiovascular Interventions. 2024. doi:10.1002/ccd.31166

BibTeX
@article{AlvarezCovarrubias2024,
  author = {Alvarez-Covarrubias, Hector A and Joner, Michael and Lutz, Marius and Xhepa, Erion and Mayr, N Patrick and Lachmann, Mark and Cassese, Salvatore and Rheude, Tobias and Pellegrini, Costanza and Kufner, Sebastian and Schunkert, Heribert and Kastrati, Adnan and Erlebach, Magdalena and Lange, Rüdiger and Ruge, Hendrik},
  title = {Outcomes after transcatheter mitral valve implantation in valve‐in‐valve, valve‐in‐ring, and valve‐in‐mitral annular calcification},
  journal = {Catheterization and Cardiovascular Interventions},
  year = {2024},
  doi = {10.1002/ccd.31166}
}
Kostenlos starten →